172 assets in Refractory Malignant Neoplasm

Therapeutic assets addressing Refractory Malignant Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ensartinib Refractory Malignant Neoplasm	National Cancer Institute (NCI)	P2	CCC (53)
Gsk-2636771 Refractory Malignant Neoplasm	National Cancer Institute (NCI)	P2	CCC (53)
Ipatasertib Refractory Malignant Neoplasm	National Cancer Institute (NCI)	P2	CCC (53)
Ivarmacitinib Refractory Malignant Neoplasm	First Affiliated Hospital of Chongqing Medical University	P2	CCC (53)
Ivosidenib Refractory Malignant Neoplasm	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Refractory Malignant Neoplasm	National Cancer Institute (NCI)	P2	CCC (53)
Osimertinib Refractory Malignant Neoplasm	Samsung Medical Center	P2	CCC (53)
Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493 Refractory Malignant Neoplasm	National Cancer Institute (NCI)	P2	CCC (53)
Rivoceranib Refractory Malignant Neoplasm	First Affiliated Hospital of Chongqing Medical University	P2	CCC (53)
Selpercatinib Refractory Malignant Neoplasm	National Cancer Institute (NCI)	P2	CCC (53)
Tafolecimab Refractory Malignant Neoplasm	Anhui Provincial Cancer Hospital	P2	CCC (53)
Thymosins Thymalfasin Refractory Malignant Neoplasm	Second Affiliated Hospital of Soochow University	P2	CCC (53)
Tisleizumab Refractory Malignant Neoplasm	Samsung Medical Center	P2	CCC (53)
Ulixertinib Refractory Malignant Neoplasm	National Cancer Institute (NCI)	P2	CCC (53)
Visugromab Refractory Malignant Neoplasm	CatalYm GmbH	P2	CCC (53)
Elraglusib Refractory Malignant Neoplasm	Actuate Therapeutics Inc.	P2	CCC (52)
Navitoclax Refractory Malignant Neoplasm	National Cancer Institute (NCI)	P1/2	CCC (52)
Pamiparib Refractory Malignant Neoplasm	M.D. Anderson Cancer Center	P1	CCC (52)
Temsirolimus Refractory Malignant Neoplasm	M.D. Anderson Cancer Center	P1	CCC (52)
Bendamustine Refractory Malignant Neoplasm	Meirav Kedmi MD	P2	CCC (51)
Entinostat Refractory Malignant Neoplasm	National Cancer Institute (NCI)	P1/2	CCC (51)
Epcoritamab Refractory Malignant Neoplasm	Dipenkumar Modi	P2	CCC (51)
ima203 Refractory Malignant Neoplasm	Immatics US, Inc.	P1/2	CCC (51)
Leflunomide Refractory Malignant Neoplasm	N.N. Petrov National Medical Research Center of Oncology	P2	CCC (51)
Lomustine Refractory Malignant Neoplasm	Actuate Therapeutics Inc.	P2	CCC (51)
Nadravaleucel Refractory Malignant Neoplasm	NKGen Biotech, Inc.	P1/2	CCC (51)
Omeprazole Refractory Malignant Neoplasm	Wake Forest University Health Sciences	P2	CCC (51)
Taselisib Refractory Malignant Neoplasm	National Cancer Institute (NCI)	P2	CCC (51)
Berzosertib Refractory Malignant Neoplasm	M.D. Anderson Cancer Center	P1/2	CCC (50)
Bet Bromodomain Inhibitor Zen-3694 Refractory Malignant Neoplasm	National Cancer Institute (NCI)	P1/2	CCC (50)
Cyclophosphamide Refractory Malignant Neoplasm	National Cancer Institute (NCI)	P1/2	CCC (50)
Fludeoxyglucose Refractory Malignant Neoplasm	Anusha Kalbasi	P1/2	CCC (50)
Cetuximab Refractory Malignant Neoplasm	National Cancer Institute (NCI)	P1	CCC (49)
ad1208 Refractory Malignant Neoplasm	Avelos Therapeutics Inc.	P1/2	CCC (48)
Autologous Dual-Target Car-T Cells Selected From The Predefined Target Library. Refractory Malignant Neoplasm	Beijing Biotech	P1/2	CCC (48)
Avelumab Refractory Malignant Neoplasm	M.D. Anderson Cancer Center	P1/2	CCC (48)
Bcma-Cart Cells Refractory Malignant Neoplasm	Institute of Hematology & Blood Diseases Hospital, China	P1/2	CCC (48)
Benzoic Acid, 4-((4-Amino-3-(4-Cyclohexyl-1-Piperazinyl)-9,10-Dihydro-9,10-Dioxo-1-Anthracenyl)Amino)- Refractory Malignant Neoplasm	VM Oncology, LLC	P1/2	CCC (48)
IMA401 Refractory Malignant Neoplasm	Immatics Biotechnologies GmbH	P1/2	CCC (48)
Lamivudine Refractory Malignant Neoplasm	Thomas Marron	P1/2	CCC (48)
Oxodotreotide Refractory Malignant Neoplasm	Fundación de investigación HM	P1/2	CCC (48)
Raltitrexed Refractory Malignant Neoplasm	China Medical University, China	P1/2	CCC (48)
snk02 Refractory Malignant Neoplasm	NKGen Biotech, Inc.	P1	CC (47)
Tislelizumab Refractory Malignant Neoplasm	Tongji Hospital	P1/2	CC (47)
Dcr-Stat3 Refractory Malignant Neoplasm	Dicerna Pharmaceuticals, Inc., a Novo Nordisk company	P1	CC (46)
Trastuzumab Deruxtecan Refractory Malignant Neoplasm	M.D. Anderson Cancer Center	P1	CC (46)
Cis-Diamminedichloroplatinum Ii Refractory Malignant Neoplasm	National Cancer Institute (NCI)	P1/2	CC (45)
dt2216 Refractory Malignant Neoplasm	Children's Oncology Group	P1/2	CC (45)
Elimusertib Refractory Malignant Neoplasm	National Cancer Institute (NCI)	P1/2	CC (45)
Immunoglobulin G4, Anti-(Human Colony-Stimulating Factor 1 Receptor) (Human-Rattus Norvegicus Monoclonal Sndx-6352 .Gamma.4-Chain), Disulfide With Human-Rattus Norvegicus Monoclonal Sndx-6352 .Kappa.-Chain, Dimer Refractory Malignant Neoplasm	OHSU Knight Cancer Institute	P1/2	CC (45)

Showing 51 to 100 of 172 assets

PreviousPage 2 of 4Next